Technology

Mick Ryan, vice president of IT at ICON plc, discusses the growing use of artificial intelligence in clinical research—from technology and data analysis to patient privacy and ethics.

In this video interview, Mark Melton, vice president of biospecimen data and operations, Slope, touches on the challenges with hand-written data collection and how they can be addressed with AI.

Industry experts discuss the use of decentralized technologies and the potential of artificial intelligence in reaching underrepresented patient populations.

In this video interview, Mark Melton, vice president of biospecimen data and operations, Slope, discusses how AI can be used to streamline sample collection and tracking.

In this video interview, Jeff Sidell, PhD, chief technology officer, Advarra, highlights the idea of consolidating clinical technology and how it may become more popular in the future.

In this video interview, Jeff Sidell, PhD, chief technology officer, Advarra, discusses the concept of data exhaust and how managing it can be simplified with artificial intelligence.

In this video interview, Jeff Sidell, PhD, chief technology officer, Advarra, talks AI and how it can automate repetitive processes.

In this video interview, Jeff Sidell, PhD, chief technology officer, Advarra, highlights how integration can simplify processes.

In this video interview, Jeff Sidell, PhD, chief technology officer, Advarra, discusses how sites are being burdened by increasingly complex technologies.

How the inclusion of measures centered on net treatment benefit can drive an effective multifaceted approach.

The potential of next-generation platforms in transforming patient recruitment.

Results from survey of 100 site personnel suggest a disconnect is present between these stakeholders.

In this video interview, Jimmy Bechtel, vice president, site engagement, SCRS, highlights how sites are bearing the burdens of cost and training with implementing new technologies.

In this video interview, Jimmy Bechtel, vice president, site engagement, SCRS, discusses challenges and trends he is currently hearing about from sites.

While recent advancements in technology are helping studies operate more efficiently, concerns around their accuracy and usability still remain.

Industry experts share their perspectives on the potential of AI in clinical trials.

In this video interview with ACT editor Andy, Studna, Silvio Galea, chief data & analytics officer, WCG, highlights the need for relevant, quality data and the challenges with needing to use multiple technologies.

Developing a strategic approach for labs that can identify and tackle global health challenges.

In this video interview with ACT editor Andy, Studna, Silvio Galea, chief data & analytics officer, WCG, touches on the usability of clinical technology.

From design and trial start-up to conduct and analysis, there is enormous potential for applications of artificial intelligence within clinical trials to have a profound impact on human health.

In a rare disease space that faces challenges in measurement quality, these technologies can enable the use of real-world data and improve study timelines.

The need to boost education, shift culture, and embrace new technologies.

Using surveys to collect various viewpoints on eConsent from ethics, sponsors, and vendors.

In this video interview with ACT editor Andy Studna, Rich Gliklich, founder of OM1 discusses automating data collection and organizing unstructured data.

Stakeholders are increasingly turning to data monitoring committees for better oversight.

In an interview with Nico Saraceno at DPHARM 2024, Munther Baara, VP strategy and innovation, EDETEK touches on the features an effective AI/ML model can provide and how they benefit data management in trials.

Panel discusses the advantages that these models can provide in adding efficiencies to the clinical trial process.

Amid the steady introduction of new tech and data advances in study conduct, the September issue of Applied Clinical Trials explores the evolving regulatory landscape governing these efforts and what companies are doing to remain compliant.

The promise and acceptance of using this AI tool in drug development is growing.

An overview of the advantages of implementing AI into clinical development and the obstacles that prevent its widespread adoption.